<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03829618</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00009727</org_study_id>
    <nct_id>NCT03829618</nct_id>
  </id_info>
  <brief_title>Lidocaine Administration During Flexible Bronchoscopy and Endobronchial Ultrasound</brief_title>
  <official_title>Lidocaine Administration During Flexible Bronchoscopy and Endobronchial Ultrasound</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess if there is decrease in cough during flexible
      bronchoscopy and endobronchial ultrasound when different modes of lidocaine administration
      are used. The modes of administration being evaluated are topical, nebulized and atomized.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">July 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cough</measure>
    <time_frame>1 day</time_frame>
    <description>Number of coughs during procedure as defined by cough requiring stopping procedure or treatment by anesthesiologist with propofol or alfentanyl</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sore Throat</measure>
    <time_frame>1 day</time_frame>
    <description>subjective sore throat as described by patient as: none, mild, moderate, severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective Cough</measure>
    <time_frame>1 day</time_frame>
    <description>subjective cough as described by patient as: none, mild, moderate, severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anesthesia time to wake up</measure>
    <time_frame>1 day</time_frame>
    <description>time in minutes from scope out until ready for transport to post anesthesia care unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>alfentanyl dosing</measure>
    <time_frame>1 day</time_frame>
    <description>Total alfentanyl dosing by anesthesia in mcg/kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>propofol dosing</measure>
    <time_frame>1 day</time_frame>
    <description>Total propofol dosing by anesthesia in mg/kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fentanyl dosing</measure>
    <time_frame>1 day</time_frame>
    <description>total fentanyl dosing by anesthesia in mcg/kg</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Bronchiectasis Adult</condition>
  <condition>Mediastinal Lymphadenopathy</condition>
  <condition>Pneumonia</condition>
  <condition>Chest--Diseases</condition>
  <condition>Infiltrates</condition>
  <condition>Bronchopulmonary Disease</condition>
  <condition>Cancer, Lung</condition>
  <arm_group>
    <arm_group_label>Topical Lidocaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>16 ml of 1% lidocaine sprayed in 4 ml aliquots to vocal cords, midtrachea, left main stem bronchus and right main stem bronchus.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nebuliser Solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2% lidocaine dosed at 2mg/kg with max dose of 160mg nebulized via jet nebulizer in operating room over ten minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nebuliser Suspension</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2% lidocaine dosed at 2mg/kg with max dose of 160mg nebulized via vibrating mesh nebulizer in operating room over ten minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical lidocaine</intervention_name>
    <description>1% lidocaine topically applied in 4 mL aliquots</description>
    <arm_group_label>Topical Lidocaine</arm_group_label>
    <other_name>Topical</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebuliser solution</intervention_name>
    <description>2% lidocaine dose at 2 mg/kg (max 160 mg) applied via jet nebulizer</description>
    <arm_group_label>Nebuliser Solution</arm_group_label>
    <other_name>Nebulizer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebuliser Suspension</intervention_name>
    <description>2% lidocaine dosed at 2 mg/kg (max 160 mg) applied via vibrating mesh nebulizer</description>
    <arm_group_label>Nebuliser Suspension</arm_group_label>
    <other_name>Atomizer</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of mediastinal and/or hilar lymphadenopathy requiring endobronchial
             ultrasound evaluation and transbronchial needle aspiration.

          -  Diagnosis of pulmonary disease requiring flexible bronchoscopy

          -  Greater than 18 years of age.

        Exclusion Criteria:

          -  Any intervention beyond flexible bronchoscopy and endobronchial ultrasound

          -  Inability to tolerate bronchoscopy.

          -  Patients that receive paralytics.

          -  Patients with neuromuscular diseases.

          -  Inability to consent for procedures.

          -  Allergies to lidocaine or any other drugs used in protocol.

          -  Existing renal insufficiency or liver disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Toth</last_name>
    <role>Principal Investigator</role>
    <affiliation>Milton S. Hershey Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lauren Ventola, MD</last_name>
    <phone>732-610-1510</phone>
    <email>lventola@pennstatehealth.psu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Penn State Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Ventola, MD</last_name>
      <phone>732-610-1510</phone>
      <email>lventola@pennstatehealth.psu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Toth, MD</last_name>
      <email>jtoth@pennstatehealth.psu.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Madan K, Biswal SK, Mittal S, Hadda V, Mohan A, Khilnani GC, Pandey RM, Guleria R. 1% Versus 2% Lignocaine for Airway Anesthesia in Flexible Bronchoscopy Without Lignocaine Nebulization (LIFE): A Randomized Controlled Trial. J Bronchology Interv Pulmonol. 2018 Apr;25(2):103-110. doi: 10.1097/LBR.0000000000000458.</citation>
    <PMID>29346249</PMID>
  </reference>
  <reference>
    <citation>Stolz D, Chhajed PN, Leuppi J, Pflimlin E, Tamm M. Nebulized lidocaine for flexible bronchoscopy: a randomized, double-blind, placebo-controlled trial. Chest. 2005 Sep;128(3):1756-60.</citation>
    <PMID>16162784</PMID>
  </reference>
  <reference>
    <citation>Wahidi MM, Jain P, Jantz M, Lee P, Mackensen GB, Barbour SY, Lamb C, Silvestri GA. American College of Chest Physicians consensus statement on the use of topical anesthesia, analgesia, and sedation during flexible bronchoscopy in adult patients. Chest. 2011 Nov;140(5):1342-1350. doi: 10.1378/chest.10-3361.</citation>
    <PMID>22045879</PMID>
  </reference>
  <reference>
    <citation>Dreher M, Cornelissen CG, Reddemann MA, Müller A, Hübel C, Müller T. Nebulized versus Standard Local Application of Lidocaine during Flexible Bronchoscopy: A Randomized Controlled Trial. Respiration. 2016;92(4):266-273. Epub 2016 Sep 10.</citation>
    <PMID>27614989</PMID>
  </reference>
  <results_reference>
    <citation>Amini S, Peiman S, Khatuni M, Ghalamkari M, Rahimi B. The Effect of Dextromethorphan Premedication on Cough and Patient Tolerance During Flexible Bronchoscopy: A Randomized, Double-blind, Placebo-controlled Trial. J Bronchology Interv Pulmonol. 2017 Oct;24(4):263-267. doi: 10.1097/LBR.0000000000000385.</citation>
    <PMID>28891835</PMID>
  </results_reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>January 24, 2019</study_first_submitted>
  <study_first_submitted_qc>February 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 4, 2019</study_first_posted>
  <last_update_submitted>July 30, 2019</last_update_submitted>
  <last_update_submitted_qc>July 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>Jennifer Toth</investigator_full_name>
    <investigator_title>Professor of Medicine and Surgery, Director of Interventional Pulmonology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Bronchiectasis</mesh_term>
    <mesh_term>Lymphadenopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

